Physician profile
Adwait Jathal
NPI 1972574333
$3,562.52
in general payments reported to CMS, 2019-2025
25 companies · $937 in 2025
The $937 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $215 · 2021: $460 · 2022: $139 · 2023: $521 · 2024: $900 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,277 · Gift: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,276.50 |
| Gift | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,665.38 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $235.04 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $233.42 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $212.74 | 2023-2025 | |
| Braintree Laboratories, INC. | $161.64 | 2019-2024 | Suflave |
| Celgene Corporation | $148.45 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.48 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $106.30 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $88.05 | 2019-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $66.35 | 2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $59.25 | 2025 | Iqirvo |
| Ardelyx, INC. | $50.99 | 2024-2025 | Ibsrela |
| Medtronic, INC. | $46.01 | 2021-2024 | Interstim |
| Intercept Pharmaceuticals, INC. | $43.44 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $41.54 | 2024 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $34.88 | 2025 | Ayvakit |
| Novo Nordisk INC | $31.78 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.27 | 2024 | Cyltezo |
| Madrigal Pharmaceuticals | $29.77 | 2025 | Rezdiffra |
| Alnylam Pharmaceuticals INC. | $27.59 | 2024 | Givlaari |
| Amgen INC. | $24.50 | 2021 | |
| Echosens North America, INC. | $23.56 | 2025 | Fibroscan |
| Redhill Biopharma INC. | $19.06 | 2021 | |
| Exact Sciences Corporation | $17.94 | 2025 | The Cologuard Plus Collection Kit |
| Axonics, INC. | $16.09 | 2023 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adwait Jathal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.